


SUPPLEMENTARY MATERIAL TO  
**Molecular dynamics-based methodological approach to clarify  
PFOA binding on human serum albumin**

ALEKSANDRA M. ĐURĐEVIĆ ĐELMAŠ<sup>1</sup>, DANILO P. TRAJKOVIĆ<sup>1</sup>, KARLA  
MILČIĆ<sup>2</sup> and MILOŠ K. MILČIĆ<sup>1\*</sup>


<sup>1</sup>University of Belgrade – Faculty of Chemistry, Studentski trg 12–16, 11158 Belgrade, Serbia  
and <sup>2</sup>Institute of Chemistry, Technology and Metallurgy, Department of Chemistry, University  
of Belgrade, National Institute of the Republic of Serbia, Njegoševa 12, 11000 Belgrade,  
Serbia

*J. Serb. Chem. Soc.* 91 (2) (2026) 129–144




**Figure S-1. PyMOL representation of the crystal structure of HSA (PDB: 1N5U).** (A) The overall structure with subdomains highlighted: Domain Ia (light pink), Domain Ib (light blue), Domain IIa (light yellow), Domain IIb (salmon), Domain IIIa (pale cyan), and Domain IIIb (pale green). (B) Binding pockets relevant to ligand interactions are labeled, including eight fatty acid binding sites (FA1–FA8), two Sudlow's drug-binding sites (Sudlow's site I and II), and an additional drug-binding pocket. Binding site annotations are based on literature-reported positions.

\* Correspondence E-mail: mmilcic@chem.bg.ac.rs




**Figure S-2. Representation of docking poses with binding energies below  $-33.4$  kJ/mol.**


Poses L7–L12 are shown on the HSA molecule (left), while the right panels present the interactions for each pose, as generated in the *Discovery Studio* program. The legend for the interaction types is provided below the depiction of the HSA crystal structure (PDB: 1N5U) with bound ligands.



**Figure S-3. RMSD of HSA during all three 1000-ns MD simulation.**



**Figure S-4.** Radius of gyration of HSA during all three 1000-ns MD simulation.



**Figure S-5.** RMSD plots for ligand (L) poses not selected as PFOA binding sites on HSA. The plots were generated from three independent MD simulations.